Remo Alessandris, PhD in Oncology and Immunology at Università degli Studi di Padova, shared a post on LinkedIn:
“HAIP chemotherapy for unresectable intrahepatic cholangiocarcinoma in Journal of Hepatology.
Pooled individual patient-level analysis of 4 prospective phase II trials – 142 patients with unresectable, liver-confined iCCA.
Hepatic artery infusion pump chemotherapy with FUDR ± systemic therapy.
- 53% partial response
- 96% disease control rate
- Median OS 26 months
- 3-year OS 28% / 5-year OS 15%
Liver control matters!
This is not yet randomized evidence – but it provides one of the most mature long-term benchmarks for HAIP in unresectable liver-confined iCCA.
Proud to be part of this international effort togheter with Merve Rousian and looking forward to building structured HAIP programs in Europe 🇪🇺
More to come!”
To which Flavio Rocha, Physician-in-chief, Knight Cancer Institute at Oregon Health and Science University, added:
“We have hepatic artery infusion therapy for intrahepatic Cholangiocarcinoma at OHSU Knight Cancer Institute”
Title: Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials
Authors: Merve Rousian, Remo Alessandris, Lauren Schleimer, Hannah Kalvin, Omar Zaki, Louise Connell, James Harding, Eileen O’Reilly, Ghassan Abou-Alfa, Neeta Vachharajani, Majella Doyle, Benjamin Tan, Adeel Khan, Ryan Fields, Stijn Franssen, Wills Filipe, Florian Buisman, Bianca Mostert, Marjolein Homs, Michail Doukas, Britte ten Haaft, Rutger-Jan Swijnenburg, Heinz-Josef Klümpen, Jeroen Hagendoorn, Nadia Haj Mohammad, Francesco Enrico D’Amico, Kevin Soares, Peter Kingham, Alice Wei, Michael D’Angelica, Mithat Gönen, William Chapman, Nancy Kemeny, Andrea Cercek, William Jarnagin, Bas Groot Koerkamp.
Other articles about GI Oncology on OncoDaily.